U.S. authorizes updated COVID booster shots for children as young as 5
Reuters
Published Oct 12, 2022 09:58AM ET
Updated Oct 12, 2022 02:15PM ET
(Reuters) -U.S. health regulators authorized the use of Omicron-tailored COVID-19 booster shots from Moderna (NASDAQ:MRNA) Inc and Pfizer Inc (NYSE:PFE) in children as young as 5, a move that will expand the government's fall vaccination campaign.
The U.S. Food and Drug Administration on Wednesday green-lighted Moderna's bivalent vaccine for those aged six and above, while Pfizer's updated shot was authorized in children aged five and above.
The U.S. Centers for Disease Control and Prevention also backed the FDA's authorization, clearing the way for the shots to be administered in children.
The redesigned bivalent booster shots from both Moderna and Pfizer target the original version as well as the BA.4 and the currently dominant BA.5 subvariants of Omicron.
"Since children have gone back to school in person and people are resuming pre-pandemic behaviors and activities, there is the potential for increased risk of exposure to the virus," said Peter Marks, head of FDA's Center for Biologics Evaluation and Research.
Overall, COVID-19 vaccination rates in the United States have stayed low among kids, with nearly 40% of children aged 5-11 vaccinated with one dose of a vaccine so far.
Pfizer/BioNTech's vaccine will be shipped immediately after the CDC's recommendation, the companies said.
Pfizer said it has the capacity to ship up to 6 million pediatric doses in the first seven calendar days, without any impact to distribution output of the doses for individuals aged 12 years and older.
The BA.5 subvariant of Omicron currently remains the dominant strain, accounting for nearly 79% of the cases in the United States.
Around 11.5 million people received the updated shots over the first five weeks of the rollout last month, which represents just 5.4% of the people aged 12 or older who are eligible to receive them.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.